Correction of technical issuing details of the final terms in the rights issue
CORRECTION: STOCKHOLM, 7 August 2023. Due to technical issuing details at Euroclear Sweden AB, a correction has been made in relation to the final terms published on 4 August 2023, with a change regarding the number of unit rights shareholders are allocated per existing ordinary share and the number of units the unit rights entitle to. The correction does not affect the subscription price or transaction size.
Existing shareholders in Moberg Pharma as of the record date, 14 August 2023, will receive sixteen (16) (previously communicated eight (8)) unit rights per one (1) existing ordinary share. Nine (9) unit rights entitle to subscription for one (1) (previously communicated two (2)) units in the Rights Issue. Each unit remains unchanged, consisting of one (1) ordinary share and one (1) warrant issued without cost. The subscription price is unchanged, SEK 5.75 per unit.
In total, a maximum of 17,470,149 (increase by 1 from previously communicated 17,470,148) units will be issued. Each unit consists of one (1) ordinary share and one (1) warrant of series 2023:1 issued without cost, which means that a maximum of 17,470,149 (increase by 1 from previously communicated 17,470,148) ordinary shares and 17,470,149 (increase by 1 from previously communicated 17,470,148) warrants of series 2023:1 will be issued. The share capital will increase by no more than SEK 17,470,149.867306 (previously communicated 17,470,148.867306). Upon full exercise of all warrants, the company’s share capital will increase by no more than SEK 17,470,149.867306 (previously communicated 17,470,148.867306).
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 - 766 60 30, e-mail: [email protected]
Mark Beveridge, VP Finance, telephone: +46 768 05 82 88, e-mail: [email protected]
About this information
The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 pm CEST on 7 August 2023.
